Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry

Younossi, Zobair M.; Yılmaz, Yusuf; Yu, Ming‐Lung; Wong, Vincent Wai‐Sun; Fernandez, Marian A.; Isakov, Vasily; Duseja, Ajay; Méndez-Sánchez, Nahúm; Eguchi, Yuichiro; Bugianesi, Elisabetta; Burra, Patrizia; George, Jacob; Fan, Jian‐Gao; Papatheodoridis, George; Chan, Wah Kheong; Alswat, Khalid; Saeed, Hamid S.; Singal, Ashwani K.; Romero–Gómez, Manuel; Gordon, Stuart C.; Roberts, Stuart K.; Kassas, Mohamed El; Kugelmas, Marcelo; Ong, Janus P.; Alqahtani, Saleh A.; Ziayee, Mariam; Lam, Brian; Younossi, Issah; Racila, Andrei; Henry, Linda; Stepanova, Maria

doi:10.1016/j.cgh.2021.11.004

Cited by 53 publications

(60 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical profile in our study is consistent with data from more extensive studies [ 45 , 46 ]. We found that BMI, waist circumference, serum triglycerides, AST, ALT, GGT, serum glucose, HbA1C, and HOMA-IR were significantly higher in patients with severe fibrosis.…”

Section: Discussionsupporting

confidence: 91%

Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Non-alcoholic fatty liver disease (NAFLD)-related severe liver fibrosis is associated with a higher risk of progressing to decompensated cirrhosis and hepatic failure and developing NAFLD-related hepatocellular carcinoma (HCC), particularly in populations with diabetes. Our pilot study aims to evaluate the performances of various noninvasive methods in predicting liver fibrosis in a population of patients with diabetes and to establish a new scoring system for the prediction of severe fibrosis (>F3). Materials and Methods: A total of 175 patients with diabetes were enrolled for liver fibrosis evaluation. Using the degree of agreement (concordance) between a noninvasive score based on serum biomarkers (NAFLD fibrosis score) and point shear-wave elastography (pSWE) as the reference method, we generated receiver operating characteristic (ROC) curves and performed a multivariate analysis to predict severe liver fibrosis. Results: In our population of patients with diabetes, gamma-glutamyltransferase (GGT), age, body mass index (BMI), the homeostatic model assessment of insulin resistance (HOMA-IR), and glycosylated hemoglobin (HbA1C) were significant predictors for the diagnosis of the F3/F4 group (area under the ROC: 0.767, 0.743, 0.757, 0.772, and 0.7, respectively; p < 0.005 for all). Moreover, the combined composite score (the sum of GGT, age, BMI, HOMA index, and HbA1C) had the highest diagnostic performance at a cut-off value of 3 (AUROC—0.899; p < 0001). The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were 91.20%, 79%, 79%, and 89%, respectively, and 89% of patients were correctly classified as having severe liver fibrosis. In contrast with the Fibrosis 4 (FIB-4) score and the AST-to-platelet ratio index (APRI), the composite score had the best accuracy in discriminating advanced fibrosis. Conclusions: The proposed composite score had a reliable and acceptable diagnostic accuracy in identifying patients with diabetes at risk of having severe fibrosis using readily available laboratory and clinical data.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus

et al. 2022

View full text Add to dashboard Cite

show abstract

“…5 The Global NAFLD Registry data on clinical and patient-reported outcomes showed that NAFLD patients in South Asia were the youngest, and had the highest employment rates and the lowest rates of MetS. 6 Calf circumference, neck circumference, chronic kidney disease, and impaired lung function were found to be associated with NAFLD in our community-based study in adults in Shanghai, China. [7][8][9][10] According to the GO ASIA initiative study, the percentages of NASH and advanced fibrosis were 62.9% and 17.2% among 1008 patients with biopsy-proven NAFLD.…”

Section: Risk Factors For and Natural History Of Nafld In Asiamentioning

confidence: 66%

Epidemiological trends and clinical characteristic of NAFLD/MAFLD in Asia

Xue

Yang

Fan

2022

J of Digest Diseases

View full text Add to dashboard Cite

“…12 NAFLD imposes a significant health burden due to its associated liver-related complications, particularly in patients with NASH and advanced liver fibrosis. 1,71 A report from the UK National Health Service Blood and Transplant Agency estimated that the incidence of decompensated NASH cirrhosis accounted for an increased proportion of patients undergoing liver transplantation (12% in 2013 compared with 4% in 1995). 72 Hepatic involvement, on the other hand, is only one aspect of NAFLD's related burden.…”

Section: Economic Burden Of Nafldmentioning

confidence: 99%

“…12 NAFLD imposes a significant health burden due to its associated liver-related complications, particularly in patients with NASH and advanced liver ﬁbrosis. 1 71…”

Section: Economic Burden Of Nafldmentioning

confidence: 99%

Nonalcoholic Fatty Liver Disease: Current Global Burden

et al. 2022

View full text Add to dashboard Cite

The map and global disease burden of chronic liver diseases are markedly changing, with non-alcoholic fatty liver disease (NAFLD) becoming the most common cause of liver affection coinciding with the current epidemics of obesity, type 2 diabetes, and metabolic syndrome. Understanding the incidence and prevalence of NAFLD is critical because of its linkage to a significant economic burden of hospitalization and changing patterns in consequences such as liver transplantation. Moreover, the long-term average healthcare expenses of NAFLD patients have exceeded those of other liver diseases. To lessen the imminent burden of NAFLD, immediate actions to raise worldwide awareness and address metabolic risk factors are required. This review summarizes key data about the global disease burden of NAFLD, modifiable and non-modifiable risk factors, and current preventive approaches.

show abstract

Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry

Cited by 53 publications

References 26 publications

Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus

Clinical Model for the Prediction of Severe Liver Fibrosis in Adult Patients with Type II Diabetes Mellitus

Epidemiological trends and clinical characteristic of NAFLD/MAFLD in Asia

Nonalcoholic Fatty Liver Disease: Current Global Burden

Contact Info

Product

Resources

About